一项由中国研究人员近日发布的最新原创性研究，有望将全球结核病预防性治疗周期由三个月缩短至 一个月。相较于WHO推荐的现行短疗程预防性治疗方案，该"中国版"超短疗程方案还有望进一步降 低治疗的药物副作用。 这项研究由国家传染病医学中心主任、广州国家实验室上海基地（上海感染与免疫科技创新中心）主 任张文宏教授团队发起。在近日刊发于Emerging Microbes & infections杂志（《新兴微生物和感 染》）、题为 "Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB)"（《新型短程利福喷丁和异烟肼方案预防性治疗中国矽肺病患者结核病 的疗效和安全性：一项试点研究》，以下简称"研究"）的文章中，该研究团队首次公布这项全新超 短程结核预防治疗方案（1H3P3方案）的有效性及安全性数据。 2025.05. 2 ...

Core Viewpoint - A new short-course preventive treatment for tuberculosis (TB) in China, known as the 1H3P3 regimen, shows promise in reducing treatment duration and side effects compared to the WHO-recommended 3HP regimen, potentially improving patient adherence and outcomes [1][4][5]. Group 1: Research Background - The study was initiated by Professor Zhang Wenhong's team and published in the journal Emerging Microbes & Infections, focusing on the efficacy and safety of the 1H3P3 regimen for TB prevention in silicosis patients [2]. - Traditional TB preventive treatments have long durations and significant side effects, leading to poor patient compliance, which affects their effectiveness and coverage [1][3]. Group 2: Treatment Comparison - The WHO recommends several treatment regimens, including a 6-9 month isoniazid monotherapy and a 3-month isoniazid plus rifapentine (3HP) regimen, but the latter has shown higher adverse reaction rates in Chinese populations [3][4]. - The 1H3P3 regimen consists of rifapentine (450mg) and isoniazid (400mg) administered three times a week for four weeks, aiming to reduce single-dose side effects and improve adherence [4][5]. Group 3: Study Results - The study included 238 participants, with only 2.5% diagnosed with active TB after three years, indicating a significant reduction in TB incidence compared to the 3HP regimen [5][6]. - The 1H3P3 regimen demonstrated a 74% reduction in the risk of developing active TB, with a treatment completion rate of 92%, significantly higher than the 54.7% completion rate for the 3HP regimen [6][7]. Group 4: Future Directions - The research team plans to conduct further studies on the 1H3P3 regimen in broader high-risk populations, including close contacts of TB patients, and aims to develop a combination formulation to simplify treatment [7][8]. - There is a need for increased government investment and collaboration across sectors to enhance public awareness and acceptance of TB preventive treatments [8].